

Myron N. Chang, Ph.D.

Personal Information:

Office Address: Room 465, Dauer Hall
228 Buckman Drive
Gainesville, FL 32611
Phone: 352 294 1947
Email: mchang@biostat.ufl.edu

Education:

Ph.D	Statistics	May 1984	University of Maryland College Park, MD	1982-84
MS.	Statistics	Dec. 1981	University of Maryland College Park, MD	1980-81

Research and Working Experience:

Professor Department of Biostatistics, University of Florida, Gainesville, FL 32610	Oct. 2010- Present
Professor Division of Biostatistics, Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL 32610	June 2005- Oct. 2010
Professor Statistics Department, University of Florida, Gainesville, FL 32611	Aug. 1997- June 2005
Associate Professor with Tenure Statistics Department, University of Florida, Gainesville, FL 32611	Aug. 1991- Aug. 1997
First Stanley S. Schor Visiting Scholar (on sabbatical leave) Merck and Co., Inc. Clinical Biostatistics and Research Data Systems	May 1992- Jan. 1993
Assistant Professor Statistics Department, University of Florida, Gainesville, FL 32611	Aug. 1986- Aug. 1991

Statistician (Research Associate)
Cancer Center Statistical Unit, Mayo Clinic

Aug. 1984- Aug. 1986

Statistician
USDA, Survey Statistics Group, Consumer Nutrition Center

May 1981- Jan. 1983

Journals Refereed:

The Annals of Statistics
Journals of American Statistical Association
Technometrics
Communications in Statistics
Controlled Clinical Trials
The American Statistician
Biometrics
Nonparametric Statistics
Statistics in Medicine

Grants and External Funding:

Research Support

Funded Externally

Name of Funding Agency: National Institute of Health
Grant Title: FGF-P Treat Post-Irradiation GI Syndrome
PI: Paul Okunieff
Role of Nominee: Investigator
Effective Dates: 04/09/2012 – 02/28/2014
Dr. Chang's share: 5%

Name of Funding Agency: National Institute of Health
Grant Title: The Role of IL 8 in Colitis-Associated Tumor initiation
PI: Emina Huang
Role of Nominee: Investigator
Effective Dates: 06/01/2010 – 03/31/2013
Dr. Chang's share: 4%

Name of Funding Agency: National Institute of Health
Grant Title: The Role of the Colitic Stem Cell Niche in Oncogenesis
PI: Emina Huang
Role of Nominee: Investigator
Effective Dates: 07/02/2010 – 04/31/2015
Direct Costs: \$1,037,500.00
Indirect Costs: \$482,440.00
Total Award: \$1,519,940.00

Dr. Chang's Direct Costs share: \$54,875.50
Dr. Chang's Indirect Costs share: \$25,517.10
Dr. Chang's Total share: \$80,392.60.

Name of Funding Agency: National Institute of Health
Grant Title: A Novel Mitigator for Lung Radiation Injury
PI: S Yang
Role of Nominee: Investigator
Effective Dates: 01/04/2010 – 02/28/2011
Direct Costs: \$610,966.00
Indirect Costs: \$241,499.00
Total Award: \$852,465.00
Dr. Chang's Direct Costs share: \$9,726.94
Dr. Chang's Indirect Costs share: \$4,523.03
Dr. Chang's Total share: \$14,249.97.

Name of Funding Agency: National Institute of Health
Grant Title: Bioactive Peptides for Mitigation of AGS and Acute Radiation Injury
PI: L Zhang
Role of Nominee: Investigator
Effective Dates: 07/01/2010 – 06/30/2011
Direct Costs: \$360,222.00
Indirect Costs: \$138,933.00
Total Award: \$499,155.00
Dr. Chang's Direct Costs share: \$9,495.78
Dr. Chang's Indirect Costs share: \$4,415.54
Dr. Chang's Total share: \$13,911.32.

Name of Funding Agency: National Institute of Health
Grant Title: CTSI
PI: D. Nelson
Role of Nominee: Investigator
Effective Dates: 07/14/2009 – 06/30/2012
Total Award: \$3,186,297.00
Dr. Chang's Direct Costs share: \$57,474.63
Dr. Chang's Indirect Costs share: \$0
Dr. Chang's Total share: \$57,474.63.

Name of Funding Agency: National Institute of Health/National Cancer Institute
Grant Title: Psychological distress in survivors of head/neck cancer
PI: H Logan
Role of Nominee: Investigator
Effective Dates: 01/26/2005 – 12/31/2007
Direct Costs: \$236,500.00

Indirect Costs: \$107,608.00
Total Award: \$344,108.00
Dr. Chang's Direct Costs share: \$13,312.03
Dr. Chang's Indirect Costs share: \$6,056.97
Dr. Chang's Total share: \$19,369.00.

Name of Funding Agency: National Institute of Health/National Cancer Institute

Grant Title: Symptom assessment after stem cell transplant

PI: J Graham-Pole

Role of Nominee: Investigator

Effective Dates: 09/30/2005 – 08/31/2007

Direct Costs: \$191,934.00

Indirect Costs: \$87,331.00

Total Award: \$279,265.00

Dr. Chang's Direct Costs share: \$5,746.00

Dr. Chang's Indirect Costs share: \$2,614.43

Dr. Chang's Total share: \$8,360.43.

Name of Funding Agency: National Institute of Health/National Cancer Institute (NIH/NCI).

Grant Title: Children's Oncology Group Statistics and Data Center

PI: J Anderson

Role of Nominee: Investigator.

Effective Dates: 03/01/2007 - 2/28/2008

Direct Costs: \$7,500,001.00

Indirect Costs: \$1,715,251.00

Total Award: \$9,215,252.00

Dr. Chang's Direct Costs share: \$40,075.00

Dr. Chang's Indirect Costs share: \$10,419.50

Dr. Chang's Total share: \$50,495.

Name of Funding Agency: National Institute of Health/National Cancer Institute (NIH/NCI).

Grant Title: Children's Oncology Group Statistics and Data Center

PI: J Anderson

Role of Nominee: Investigator.

Effective Dates: 1/1/2003 to 2/28/2007

Annual Subcontract Direct Costs: \$5,610,286.00

Annual Subcontract Indirect Costs: \$1,129,169.00

Annual Subcontract Total Award: \$6,739,455.00

Dr. Chang's Direct Costs share: \$221,483.33

Dr. Chang's Indirect Costs share: \$55,370.84

Dr. Chang's Total share: \$276,854.17.

Funded Internally

Name of Institute: UF CME
 Grant Title: Surgical Outcomes Following colon and Rectal Surgery, UF
 CME Clinical Quality Award Program
 Role of Nominee: Co-Investigator
 Period: 07/01/2010 through 06/31/2012
 Dr. Chang's share: 8% FTE.
 Total Funding: \$11,368.00

Name of Institute: UF Department of Medicine
 Role of Nominee: PI, provide statistical support
 Period: 04/01/2012 through present
 Dr. Chang's share: 5% FTE.
 Total Funding:

Name of Institute: UF Shands Cancer Center
 Role of Nominee: PI, provide statistical support to UFSCC
 Period: 07/01/2007 through present
 Dr. Chang's share: 65% FTE.
 Total Funding: \$675,282.78

Name of Institute: UF Shands Cancer Center
 Role of Nominee: PI, provide statistical support to UFSCC
 Period: 07/01/2003 through 06/30/2007
 share: 50% FTE.
 Total Funding: \$324,956.51

Pending Grant Proposals

Title of project	Agency	Prime PI	Proposed Budget Amount	Duration of the project	FTE
Role of Glucose in Pathophysiologic Mechanism of Radiation Induced Gastrointestinal Toxicity	NIH	Dr. Nelson	\$77,108	09/01/11- 08/30/16	5%
Early Detection and Curative Treatment of Breast Cancer	Bank Head Coley	Dr. Okunieff	\$9,914	07/01/11 - 06/30/12	5%
Formulation of a drink to improve nutritional status following radiology	Bank Head Coley	Dr. Okunieff	\$19,829	07/01/11 - 06/30/12	10%
Novel Approaches to	NIH	Dr. Zhang	\$19,829		5%

Determine the Interaction of Polymicrobial Infection				09/01/11 - 08/30/16	
FGF-P to treat post - irradiation GI syndrome	NIH	Dr. Zhang	\$29,484	09/01/11 -08/31/13	5%
Apply Multiplex Technologies And Cluster Analysis For Detection Of Residual Leukemia And Early Stages Of Hematopoietic Stem Cell Disorders In Clinical Specimens	NIH	Dr. Li	\$85,601	04/01/12 - 03/31/17	5%
The Role of Il8 in colitis-associated tumor initiation	NIH	Dr. Huang	\$138,487	04/01/12- 03/31/17	8%
A mitigatory agent for lung inflammation and fibrosis	NIH	Dr. Huang	\$84,054	04/01/12 - 03/31/17	8%
Phase II surveillance imaging trial for distant metsases in Stage III and IV breast cancer patients	NIH	Dr. O'Dell	\$29,163	04/01/12 - 03/31/14	5%
	NIH	Dr. Kusmartsev	\$9,806	7/1/2012-6/30/2013	5%
Triptolide, a Potent Anti-Cancer and Anti-inflammation Agent	NIH	Dr. Zhang	\$76,268	7/1/2012-6/30/2017	5%
Contribution of US Nativity to Prostate Cancer and care Among Black men	ACS	Dr. Odedina	\$124,948	5 years	10%
A Novel Multiplex Assay to Detect Bladder Cancer in Voided Urine	NCI/NIH	Dr. Rosser	\$124,948	5 years	10%
Creation of an Autologous Human Anal Sphincter	NIH	Dr. Huang	\$19,612	1 year	10%
RaDose: Combination of Plasma DNA and White Cells as a Point-of-Care Biodosimeter	BARDA	Dr. Okunieff	\$152,536	7/1/2012-6/30/17	20%

Publications:

Refereed Statistical Research Papers

1. **Chang MN** and PC O'Brien (1986). Confidence Intervals Following Group Sequential Tests. *Controlled Clinical Trials*, 7, 18-26.
2. **Chang MN** and GL Yang (1987). Strong Consistency of a Nonparametric Estimator of the Survival Function with Doubly Censored Data. *Annals of Statistics*, 15, 1536-1547.
3. **Chang MN**, TM Therneau, HS Wieand, and SS Cha (1987). Designs for Group Sequential Phase II Clinical Trials. *Biometrics*, 43, 865-874.
4. **Chang MN** (1989). Confidence Intervals for a Normal Mean Following a Group Sequential Test. *Biometrics*, 45, 247-254.
5. **Chang MN**, HS Wieand, and VT Chang (1989). The Bias of the Sample Proportion Following a Group Sequential Phase II Clinical Trial. *Statistics in Medicine*, 8, 563-570.
6. **Chang MN** and PV Rao (1989). Berry Esseen Bound for the Kaplan-Meier Estimator. *Communication in Statistics, Theory and Method*, 18, 4647-4664.
7. **Chang MN** (1990). Weak Convergence of a Self-Consistent Estimator of the Survival Function with Doubly Censored Data. *Annals of Statistics*, 18, 391-404.
8. Therneau TM, HS Wieand, and **MN Chang** (1990). Optimal Designs for a Grouped Sequential Binomial Trial. *Biometrics*, 46, 771-783.
9. Yang GL and **MN Chang** (1990). A Stochastic Model for Analyzing Prevalence Surveys of Hepatitis A Antibody. *Mathematical Biosciences*, 98, 157-169.
10. **Chang MN** (1991). Moments of the Kaplan-Meier Estimator. *Sankhya, Series A*, 53, 27-50.
11. **Chang MN** (1991). On Weak Convergence of an Estimator of the Survival Function When New Is Better Than Used of a Specific Age. *Journal of the American Statistical Association*, 86, 173-178.
12. **Chang MN** (1991). Edgeworth Expansion for the Kaplan-Meier Estimator. *Communications in Statistics, Theory and Method*, 20, 2479-2494.

13. **Chang MN** and PV Rao (1992). On the Estimation of a Survival Function When New Is Better Than Used of a Specified Age. *Journal of Nonparametric Statistics*, 2, 45-58.
14. **Chang MN** and PV Rao (1993). Improved Estimation of Survival Functions in the New-Better-Than Used Class. *Technometrics*, 35, 192-203.
15. Shih WJ, H Quan, and **MN Chang** (1994). Estimation of the Mean When Data Contain Non-Ignorable Missing Values From a Random Effects Model. *Statistics and Probability Letters*, 19, 249-257.
16. **Chang MN**, HA Guess, and JF Heyse (1994). Reduction in Burden of Illness: A New Efficacy Measure for Prevention Trials. *Statistics in Medicine*, 13, 1807-1814.
17. Chung D, and **MN Chang** (1994). An Isotonic Estimator of the Baseline Hazard Function in Cox's Regression Model Under Order Restriction. *Statistics & Probability Letters*, 21, 223-228.
18. **Chang MN** and JJ Shuster (1994). Interim Analysis For Randomized Clinical Trials: Simulating the Predictive Distribution of the Logrank Test Statistic. *Biometrics*, 50, 827-833.
19. **Chang MN**, AL Gould, and SM Snapnin (1995). P-values for Group Sequential Testing. *Biometrika* 82, 650-654.
20. **Chang MN** (1996). Optimal Designs for Group Sequential Clinical Trials. *Communications in Statistics, Theory and Methods* 25, Number 2, 361-380.
21. **Chang MN** (1996). Exact Distribution of the Kaplan-Meier Estimator Under the Proportional Hazards Model. *Statistics & Probability Letters*, 28, 153-157.
22. **Chang MN** (1996). On the Asymptotic Normality of Isotonic Estimators for the Generalized Failure Rate Function. *Communications in Statistics, Theory and Methods*, 25, Number 10, 2239-2250.
23. **Chang MN** and D Chung (1998). Isotonic Window Estimators of the Baseline Hazard Function in Cox's Regression Model under Order Restriction. *Scandinavian Journal of Statistics*, Vol. 25: 151-161.
24. Gieser P, **MN Chang**, PV Rao, JJ Shuster, and J Pullen (1998). Modeling Cure Rate Using the Gompertz Model with Covariate Information. *Statistics in Medicine*, 17: 831-839.

25. **Chang MN**, IK Hwang, and WJ Shih (1998). Group Sequential Designs Using Both Type I and Type II Error Probability Spending Functions. *Communication in Statistics, Theory and Method*, 27(6): 1323-1339.
26. **Chang MN**, JJ Shuster, and JL Kepner (1999). Group Sequential Designs for Phase II Clinical Trials with Historical Controls. *Controlled Clinical Trials*, 20: 353-364.
27. Wu RL, CX Ma, **MN Chang**, RC Littell, SS Wu, M Huang, M. Wang, and G Casella (2002). A logistic mixture model for detecting major genes governing growth trajectories. *Genetical Research*, 79:235-345.
28. Wu RL, CX Ma, MC Yang, **M Chang**, U Santra, SS Wu, M Huang, M Wang and G Casella (2003). Quantitative trait loci for growth in populus. *Genetical Research*, 81:51-64.
29. Kepner JL and **M Chang** (2003). On the Maximum Total Sample Size of a Group Sequential Test about Binomial Proportions. *Statistics & Probability Letters*, 62:87-92.
30. Lin M., XY Lou, **M Chang**, and RL Wu (2003). A General Statistical Framework for Mapping Quantitative Trait Loci in Non-Model Systems: Issue for Characterizing Linkage Phase. *Genetics*, 165:901-913.
31. **Chang MN**, JJ Shuster, and JL Kepner (2004). Sample Size Based on Exact Unconditional Test for Phase II clinical Trials with Historical Controls. *Journal of Biopharmaceutical Statistics*, 14:189-200.
32. **Chang MN** (2004). Improved Confidence Intervals for a Binomial Parameter following a Group Sequential Phase II Clinical Trial. *Statistics in Medicine*, 23: 2817-2826.
33. Shuster JJ, **M Chang**, and L Tian (2004). Design of Group Sequential Clinical Trials with Ordinal Categorical Data Based on the Mann-Whitney-Wilcoxon Test. *Sequential Analysis*, 23, No. 3: 413-426.
34. Kepner JL and M Chang (2004). Samples of Exact k-stage Group Sequential Designs for Phase II and Pilot Studies. *Controlled Clinical Trials*, 25: 326-333.
35. London WB and **M Chang** (2005) One- and Two-Stage Designs for Stratified Phase II Clinical Trials. *Statistics in Medicine*, 24: 2597-2611.
36. London WB and **M Chang** (2006) Comparison of Bayesian and Frequentist Approaches to Stratified Phase II Designs. *Statistics in Medicine* 25, 3222-3223.

37. **Chang MN**, M Devidas, and J Anderson (2007). One- and two- stage designs for phase II window studies. *Statistics in Medicine*, 26: 2604-2614.
38. Zeng YR, JH Li, CG Wang, **MN Chang**, R Yang, and RL Wu (2007). Genetic Mapping quantitative trait loci. In: *Principles & Practices of Plant Genomics*. (C Kole and AG Abbott, eds). Science Publishers, Northants, UK (invited).
39. Shuster JJ, **MN Chang** (2008). Second guessing clinical trial designs. *Sequential Analysis*, Vol. 49, Issue 2: 306-314.
40. Shuster JJ, **MN Chang** (2008). Author's responses. (10 page discussion in response to 8 distinguished discussants, including the former lead biostatistician from the FDA.) *Sequential Analysis*, Vol. 49, Issue 2: 68-77.
41. **Chang MN** (2009). Estimation of multiple response rates in phase II clinical trials with missing observations. *Journal of Biopharmaceutical Statistics*, Vol (:791-802.
42. **Chang MN**, RL Wu, SS Wu, G Casella (2009). Score statistics for mapping quantitative trait loci. *Statistical Applications in Genetics and Molecular Biology*. Vol. 8, Issue1, art 16.
43. Wen S, CG Wang, A Berg, Y Li, **MN Chang**, RB Filligim, MR Wallace, R Staud, and RL Wu (2009). Modeling genetic imprinting effects of DNA sequences with multilocus polymorphism data. *Algorithm for Molecular Biology*, 4:11.
44. Li Y, A Berg, **MN Chang**, P Du, K Ahn, D Mauger, D Liao, and R Wu (2009). A Statistics model for genetic mapping of viral infection by integrating epidemiological behavior. *Statistical Applications in Genetics and Molecular Biology* 8(1): Article 38.
45. Sin-Ho Jung and MN Chang (2011). Two-stage phase II clinical trials with heterogeneous patient populations. *Journal of Biopharmaceutical Statistics*, 22:312-328.
46. Yao Li, Y Guo, J Wang, W Hou, MN Chang, D Liao, R Wu (2011). A statistical design for testing transgenerational genomic imprinting in natural human populations. *PloS ONE*.
47. Chang, MN (2011). Testing statistical hypotheses on stochastic ordering of discrete distributions. *Sequential Analysis*, 30:249-260.
48. Chang, MN, SH Jung, and S Wu (2011). Two-stage designs with additional futility tests for phase II clinical trials with heterogeneous patient population. *Sequential Analysis*, 30:338-349.

49. **Chang MN**, J Shuster, and W Hou (2012). Improved two-stage tests for stratified phase II cancer clinical trials. *Statistics in Medicine*. Accepted.

Refereed Medical Research Papers Coauthored by M. N. Chang

50. Creagan, ET, JH Edmonson, DL Ahmann, and **MN Chang** (1985). Phase II Study of Mitomycin in Disseminated Malignant Melanoma. *Cancer Treatment Reports*, 69(12), 1451-1452.
51. Ingle, JN, JE Krook, SJ Green, TP Kubista, LK Everson, DL Ahmann, **MN Chang**, HF Bisel, HE Windschitl, DI Twito, and DM Pfeifle (1986). Randomized Trial of Bilateral Oophorectomy Versus Tamoxifen in Premenopausal Women with Metastatic Breast Cancer. *Journal of Clinical Oncology*, 4(2), 178-185.
52. Creagan, ET, DL Ahmann, S Frytak, HJ Long, **MN Chang**, and LM Itri (1986). Phase II Trials of Recombinant Leukocyte A Interferon in Disseminated Malignant Melanoma: Results in 96 Patients. *Cancer Treatment Reports*, 70(5), 619-624.
53. Creagan, ET, **MN Chang**, HJ Long, and J Rubin (1986). A Phase II Clinical Trial of the Combination Mitomycin C, Adriamycin, and CIS-Diamminedichloroplatinum in Patients with Advanced Upper Aerodigestive Cancer. *Head and Neck Surgery*, Jan/Feb, 1986, 153-158.
54. Ingle JN, SJ Green, DL Ahmann, HJ Long, JH Edmonson, J rubin, **MN Chang**, and ET Creagan (1986). Randomized Trial of Tamoxifen Alone or Combined with Aminoglutethimide and Hydrocortisone in Women With Metastatic Breast Cancer. *Journal of Clinical Oncology*, 4(6), 958-964.
55. Ingle, JN, HJ Long, AJ Schutt, and **MN Chang** (1986). Evaluation of Bisantrene Administered by 72-hour Infusion in Women with Metastatic Breast Cancer. *Journal of Clinical Oncology*, 9(5), 379-381.
56. Creagan, ET, **MN Chang**, HJ Long, and J Rubin (1987). Phase II Clinical Trial of the Combination VP-16, Bleomycin, and CIS-Diammin-edi-chloroplatinum in Patients with Advanced Upper Aerodigestive Squamous Cell Carcinoma. *Head and Neck Surgery*, March/April, 1987, 223-226.
57. Edmonson JH, HJ Long, ET Creagan, S Frytak, SA Sherwin, and **MN Chang** (1987). Phase II Study of Recombinant Gamma-Interferon in Patients with Advanced Nonosseous Sarcomas. *Cancer Treatment Reports*, 71(2): 211-213.

58. Creagan ET, DL Ahmann, S Frytak, HJ Long, **MN Chang**, and LM Itri (1987). Three Consecutive Phase II Studies of Recombinant Interferon Alfa-2a in Advanced Malignant Melanoma: Updated Analysis. *Cancer*, 59, 638-646.
59. Morton RF, ET Creagan, MH Veeder, DL Elson, JA Laurie, RA Nelimark, and **MN Chang** (1987). Phase II Study of the Combination of Carmustine and 6-Thioguanine in Advanced Malignant Melanoma. *Cancer Treatment Reports*, 71(4), 429-430.
60. Morton RF, ET Creagan, SA Cullinan, JA Mailliard, L Ebbert, MH Veeder, and **MN Chang** (1987). Phase II Studies of Single-Agent Cimetidine and the Combination N-Phosphonacetyl-L-Aspartate (NSC-224131) Plus L-Alanosine (NSC-153353) in Advanced Malignant Melanoma. *Journal of Clinical Oncology*, 5(7), 1078-1082.
61. Creagan ET, DL Ahmann, HJ Long, S Frytak, SA Sherwin, and **MN Chang** (1987). Phase II Study of Recombinant Interferon-Gamma in Patients with Disseminated Malignant Melanoma. *Cancer Treatment Reports*, 71(9), 843-844.
62. Ravindranath Y, AM Yeager, **MN Chang**, et al (1996). Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. *New England Journal of Medicine*, 334: 1428-1434.
63. "A Phase II Study of 13-Cis Retinoic Acid (CRA) in Juvenile Myelomonocytic Leukemia (JMML). A Pediatric Oncology Group Study." *Blood* (1997); 90: 346a.
64. Naumovski L, G Martinovsky, C Wong, **MN Chang**, Y Ravindranath, H Weinstein, and G Dahl (1998), BCL-2 Expression Does Not Correlate With Patient Outcome in Pediatric Acute Myelogenous Leukemia. *Leukemia Research*, Vol. 22, No. 1: 81-87.
65. Raimondi SC, **MN Chang**, Y Ravindranath, FG Behm, MV Gresik, CP Steuber, HJ Weinstein, and AJ Carroll (1999). Chromosomal Abnormalities in 478 children with Acute Myeloid Leukemia: clinical characteristics and Treatment Outcome in a Cooperative Pediatric Oncology group Study-POG 8821. *Blood*, 94(11): 3707-3717.
66. Parsons SK, S Gelber, BF Cole, Y Ravindranath, A Ogden, AM Yeager, **M Chang**, J Shuster, HJ Weinstein, and RD Gelber (1999). A Q-Twist Analysis of the Pediatric Oncology Group Study 8821. *Journal of Clinical Oncology*, 17(7): 2144-2152.
67. Taub JW, X Huang, LH Matherly, ML Stout, SA Buck, GV Massey, DL Becton, **MN Chang**, HL Weinstein, Y Ravindranath (1999). Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Difference between Down

- Syndrome and non-Down Syndrome Blast Cells Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin. *Blood*, 94: 1393-1400.
68. **Chang MN**, SC Raimondi, Y Ravindranath, AJ Carroll, B Camitta, MV Gresik, CP Steuber, and HJ Weinstein (2000). Prognostic Factors in Children and Adolescents with Acute Myeloid Leukemia (excluding children with Down Syndrome and Acute Promyelocytic Leukemia): Univariate and Recursive Partitioning Analysis of Patients Treated on Pediatric Oncology Group (POG) Study 8821. *Leukemia*, 14: 1201-1207.
 69. Dahl GV, NJ Lacayo, N Brophy, K Dunussi-Joannopoulos, HJ Weinstein, **MN Chang**, BI Sikic, and RJ Arceci (2000). Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients with Recurrent or Refractory Acute Myeloid Leukemia. *Journal of Clinical Oncology*, 18, 9: 1867-1875.
 70. Haga SB, S Fu, J Kasp, DD Ross, DM Williams, WD Hawkins, F Behm, FW Ruscetti, **MN Chang**, BD Smith, D Becton, SC Raimondi, and PE Berg (2000). BP1, a new Homeobox Gene, Is Frequently Expressed in Acute Leukemia. *Leukemia*, 14: 1867-1875.
 71. Bell BA, **MN Chang**, and HJ Weinstein (2001). A Phase II Study of Homoharringtonine for the Treatment of Children with Refractory or Recurrent Acute Myelogenous Leukemia: A Pediatric Oncology Group Study. *Med. Pediat. Oncol.* 37: 103-107.
 72. Lacayo NJ, BL Lum, DL Becton, H Weinstein, Y Ravindranath, **MN Chang**, L Bomgaars, SJ Lauer, BI Sikic, and GV Gahl (2002). Pharmacokinetic Interaction of Cyclosporine with Etoposide and Mitoxantrone in Children with Acute Myeloid Leukemia. *Leukemia*, 16, Number 5: 920-927.
 73. Lacayo NJ, S Meshinichi, P Kinnunen, R Yu, Y Wang, CM Stuber, L Douglas, R Wahab, DL Becton, H Weinstein, **MN Chang**, CL Williams, JP Radich, R Tibshirani, Y Ravindranath, BI Sikic, and GV Dahl (2004). Gene Expression profiles at diagnosis in de novo children AML patients identify FLT3 mutations with good clinical outcomes. *Blood*, 104: 2646-2654.
 74. Laver JH, JM Kravaka, RE Hutchison, **MN Chang**, J Kepner, M Schwenn, N Tarbell, S Desai, S Weitzman, HJ Weinstein, SB Murphy (2005). Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. *Journal of Clinical Oncology*, 20: 541-547.
 75. Becton, D, GV Dahl, Y Ravindranath, **MN Chang**, FG Behm, SC Raimondi, DV Head, KC Stine, NJ Lacayo, BV Sikic, RJ Arceci, and H Weinstein (2006). Randomized use of cyclosporine A to modulate P-glycoprotein in children with

- AML in remission: Pediatric Oncology Group Study 9421. *Blood*, 107: 1315-1324.
76. Massey, GV, A Zipursky, **MN Chang**, JJ Doyle, S Nasim, JW Taub, Y Ravindranath, G Dahl, and HJ Weinstein (2006). A prospective study of the natural history of transient leukemia in neonates with Down syndrome: a Children's Oncology Group study POG-9481. *Blood*, 107(12): 4606-4613.
77. Ravindranath, Y, **MN Chang**, CP Steuber, D Becton, G Dahl, C Civin, B Camitta, A Carroll, SC Raimondi, HJ Weinstein. (2006) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. *Leukemia*, 19(12):2101-2116.
78. Anai S, CS West, **MN Chang**, K Nakamura, J Pendleton, CJ Rosser (2007). Outcomes of men present with elevated serum PSA to an inner-city hospital. *Journal of the National Medical Association*, Vol. 199, No 8: 895-899.
79. Eksioglu EA, SS Mahmood, **MN Chang**, V Reddy (2007). GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type1 proinflammatory response. *Experimental Hematology*, Vol. 35, Issue 9: 1163-1171.
80. Hasle H, TA Alonzo, A Auvrignon, C Behar, **MN Chang**, et al (2007). Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. *Blood*, 109: 4641-4647.
81. Nasr MR, JH Laver, **MN Chang**, RE Hutchison (2007). Expression of anaplastic lymphoma kinase (ALK), tyrosine-phosphorylated STAT3 and associated factors in pediatric anaplastic large cell lymphoma. *American Journal of Clinical Pathology*, 127:770-778.
82. Brown P, E McIntyre, R Rau, S Meshinchi, N Lacago, G Dahl, TA Alonzo, **MN Chang**, RJ Arceci, D Small (2007). The incidence and clinical significance of nucleophosmin mutations in childhood AML. *Blood*, 110: 979-985.
83. Savason S, S Buck, SC Raimondi, H Weinstein, **MN Chang**, Y Ravindranath (2007). CD 36 expression in children with acute megakaryoblasts leukemia and *in vitro* drug sensitivity. *Leukemia and Lymphoma*, Vol. 47, Issue 10: 2004-2005.
84. Liu H, CM Yuan, JH Pac, RC Braylan, **MN Chang**, JR Wingard, and JJ Moreb (2008). Flow cytometric disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. *Leukemia and Lymphoma*, Vol. 49, Issue 2: 305-314.

85. O'Brien MM, JW Taub, **MN Chang**, et al (2008). Cardiomyopathy in children with Down's syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. *Journal of Clinical Oncology*, 414-420.
86. Anai S, K Nakamura, **MN Chang**, J Pendleton, S Yacoub, CJ Rosser (2008). The feasibility of expectant management in inner-city men with newly diagnosed localized prostate cancer. *The Journal of Health Care for the Poor and Underserved*, Vol. 19, Number 1: 164-170.
87. Hutchison RE, JH Laver, **MN Chang**, T Muzzafar, S Desai, et al (2008). Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: A Children's Oncology Group Study. *Pediatric Blood and Cancer*. Vol. 51, Issue 1: 29-33.
88. Pendleton J, WW Tan, S Anai, **MN Chang**, W Hou, KT Shiverick, and CJ Rosser (2008). Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. *BMC Cancer* 2008, 8:132.
89. Pendleton J, S Anai, K Nakamura, **MN Chang**, A Grissett, CJ Rosser (2008). Prostate cancer knowledge and screening attitudes of inner-city men. *Journal of Cancer Education*. Vol23 (3): 172-179.
90. Pendleton J, RW Curry, A Kaserian, **MN Chang**, et al (2008). Knowledge and attitudes of primary care physicians regarding prostate cancer screening. *Journal of the National Medical Association*. 100(6): 666-670.
91. Kogenta Nakamura, KA Iczkowski, **M Chang**, J Pendleton, S Anai, NBP Le, and CJ Rosser (2009). Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. *BMC Urology* 2009, 9:12.
92. Elaine Coustan-Smith, JT Sandlund, SL Perkins, H Chen, **MN Chang**, M Abromowitch, and D Campana (2009). Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: A report from the Children's Oncology Group. *Journal of Clinical Oncology*. Vol27, No27: 3533-3539.
93. Vincent EM, J Marshall, S Lauren, NH Steven, **MN Chang PhD**, EM Copeland, and SR Grobmyer (2009). Magnetic Resonance Imaging for Axillary Staging in Patients with Breast Cancer. *Journal of Magnetic Resonance Imaging*. Vol. 30, Issue 2: 309-312.
94. T Griffin, S Weitzman, H Weinstein, **MN Chang**, et al (2009). A study of Rituximab and Ifosfamide, Carboplatin, and Etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Pediatric Blood & Cancer*. Vol.52, Issue1: 177-181.

95. Farese JP, J Kirpensteijn, M Kik, NJ. Bacon, SS Waltman, B Seguin, M Kent, J Liptak, R Straw, **MN Chang**, Y Jiang, and SJ. Withrow (2009). Biologic Behavior and Clinical Outcome of 25 dogs with Canine Appendicular Chondrosarcoma Treated with Amputation: A Veterinary Society of Surgical Oncology Retrospective Study. *Veterinary Surgery*: 38: 914-919.
96. Grobmyer SR, AW Hemming, N Harris, K Behrns, H Logan, RD Kim, **MN Chang**, WG Cance, SN Hochwald (2009). A Pilot Prospective Randomized Trial of Postoperative Epoetin Alfa in Patients Undergoing Major Operation for Upper Gastrointestinal Malignancy. *American Journal of Clinical Oncology*. 32(6): 570-573.
97. Balgobind BV, J Harbott, SC Raimondi, M Zimmermann, TA Alonzo, A Auvrignon, HB Beverloo, **MN Chang** et al (2009). Novel prognostic subgroups in childhood 11q23/MLL rearranged acute myeloid leukemia: results of an international retrospective study. *Blood*. Vol114, No12: 2489-2496.
98. Marsh RW, T George, T Siddiqui, WM Mendenhall, R Zlotecki, W Cance, S Grobmyer, S Hochwald, **MN Chang**, Larson B, King J (2010). A Phase II Trial of Neo-adjuvant Capecitabine Combined with Hyperfractionated Accelerated Radiation Therapy in Locally Advanced Rectal Cancer. *American Journal of Clinical Oncology*. 33(3): 251-256.
99. O'Brien MM, NJ Lacayo, BL Lum, S Kshirsagar, Y. Ravindranath, S Buck, M Berstein, H Weistein, **MN Chang**, RJ Arceci, BI Sikic, and GV Dahl (2010). Phase I study of valspodar with mitoxantrone and etoposide in children with refractory and relapsed acute leukemia: results of Children's Oncology Group Study POG 9423. *Pediatric Blood & Cancer*. 54(5): 694-702.
100. Pollard J, T Alonzo, R Gerbing, P Ho, R Zeng, Y Ravindranath, G Dahl, N Lacayo, D Becton, **MN Chang** et al (2010). Prevalence and prognostic significance of KIT mutations in pediatric core binding factor AML patients enrolled on serial pediatric cooperative trials for de novo AML. *Blood*, 115: 2372-2379.
101. Salmasinia D, **MN Chang**, JR Wingard, W Hou, and **JS Moreb** (2010). Combination of IFN-alpha/Gm-CSF as a maintenance therapy for multiple myeloma patients after autologous stem cell transplantation (ASCT): A prospective phase II study. *Clinical Medicine Insights: Oncology*, 4:117-125.
102. Champagne MA, CH Fu, **MN Chang**, H Chen, RB Gerbing, TA Aloon, LD Cooley, NA Neerena, V Oehler, C Wood, ME French, RJ Arceci, FO Smith, and ML Bernstein (2011). High dose imatinib for children with de novo chronic phase myelogenous leukemia: A report from the Children's Oncology Group. *Pediatric Blood & Cancer*, 57: 56-62.

103. Urbanek C, S Goodison, **MN Chang**, S Porvasnik, N Sakamoto, C Li, SK Boehlein, and CJ Rosser (2011). Detection of antibodies directed at M. hyorhinitis p37 in the serum of men with newly diagnosed prostate cancer. *BMC Cancer*, 11:233-238.
104. Coenen EA, SC Raimondi, J Harbott, M Zimmermann, TA Alonzo, A Auvrignon, HB Beverloo, **MN Chang**, et al (2011). Prognostic significance of additional cytogenetic aberrations in 773 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. *Blood*, 117:7102-7111.
105. Qiu Y, DA Stavreva, Y Luo, A Indrawan, **MN Chang** and GL Hager (2011). Dynamic interaction of HDAC1 with a glucocorticoid receptor regulated gene is modulated by the activity state of the promoter. *Journal of Biology Chemistry*, 286:7641-7647.
106. Draganov PV, **MN Chang**, A Alkhasawneh, LR Dixon, J Lieb, et al (2012). Randomized controlled trial of standard versus jumbo biopsy forceps for polypectomy of small sessile colorectal polyps. *Gastrointestinal Endoscopy*, 75:118-126.
107. Carilli, AR, MW Sugrue, EH Rosenau, **MN Chang**, D Fisk, M Medei-Hill, K Williams, L Wiggins, and JR Wingard (2012). African American adult donors respond to granulocyte-colony-stimulating factor with neutrophil and progenitor cell yields comparable to those of Caucasian and Hispanic donors. *Transfusion*, 52:166-172.
108. Rosenau EH, MW Sugrue, M Holler, D Fisk, SS Kelly, **MN Chang**, W Hou, L Eldjerou, W Slayton, CR Cogle, and JR Wingard. Characteristics of thawed autologous umbilical cord blood. *Transfusion*. Accepted.
109. Chaleff S, CA Hurwitz, **MN Chang**, G Dahl, TA. Alonzo, H Weinstein (2012). Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with relapsed acute myeloid leukemia: A Pediatric Oncology Group Study. *British Journal of Hematology*, 156: 649-655.
110. Logan HL, SL Tomar, **MN Chang**, GE Turner, WM Mendenhall, CE Riggs. Comparison group for 5-year oral and pharyngeal cancer survivors: Two methods. *BMC Medical Research Methodology*, Accepted.
111. Goodison S, **MN Chang**, Y Dai, S Ross, V Urquidi, CJ Rosser. Multi-analyte assay for the non-invasive detection of bladder cancer. *Journal of Urology*. Accepted.

112. Urquidi V, J Kim, **MN Chang**, Y Dai, ED Wolfson, S Goodison, **CJ Rosser**. IL-8 as a urinary biomarker for the Detection of Bladder Cancer. BMC Urology. Accepted.
113. Urquidi V, J Kim, **MN Chang**, Y Dai, **CJ Rosser**, S Goodison. CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer. PLoS ONE. Accepted.
114. Urquidi V, S Goodison, J Kim, **MN Chang**, Dai Y, **CJ Rosser**. Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urology. Accepted.
115. O'Brien MM, X Cao, S Pounds, GV Dahl, SC Raimondi, NJ Lacayo, J Taub, **MN Chang**, HJ Weinstein, Y Ravindranath, H Inaba, D Campana, CH Pui, and JE Rubnitz. Prognostic features in acute megakaryoblastic leukemia in children without down syndrome: A report from the AML02 multicenter trial and the Children's Oncology Group study POG 9421. Leukemia. Accepted.

Non-Referred Publications

116. London WB and **MN Chang** (2001). Design for Stratified Phase II Clinical Trials. American Statistical Association 2001 Proceedings of the Biometrical Section.
117. Ravindranath Y, **MN Chang**, AJ Carroll, CP Steuber, B Camitta, and H Weinstein (2001). Prognostic Factors and Patterns of Failure in Children Acute Myeloid Leukemia: Experience on Pediatric Oncology Group Study #8821. In Acute Leukemias VIII, edited by T. Buchner, W. Hiddemann, B. Worman, G. Schellong, J. Ritter, and U. Creutzfeldt. Springer-Verlag Berlin Heidelberg.
118. Hurwitz CM, **M Chang**, J Graham, H Young, and H Weinstein (2002). Timed-sequential remission induction and intensification therapy followed by stem cell rescue for children AML: A POG pilot study. Proc ASCO, 21:1553a.
119. London WB and **MN Chang** (2003). One- and Two-Stage Design for Stratified Phase II Clinical Trials. American Statistical Association 2003 Proceedings of the Biometrical Section.
120. **Chang, MN**, K Gardner, M Abromowitch. Fall 2004 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.

121. **Chang, MN**, K Gardner, JM Kraveka, Fall 2004 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
122. **Chang, MN**, K Gardner, CH Fu, MA Champagne. Fall 2004 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
123. **Chang, MN**, K Gardner, RD Castleberry. Fall 2004 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
124. **Chang, MN**, K Gardner, CH Fu, MA Champagne. Spring 2004 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
125. **Chang, MN**, K Gardner, C Hurwitz. Spring 2004 COG Study Progress Report, POG 9720: A Phase II Study of Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia.
126. **Chang, MN**, K Gardner, RD Castleberry. Spring 2004 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
127. **Chang, MN**, K Gardner, M Abromowitch. Spring 2004 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.
128. **Chang, MN**, K Gardner, JM Kraveka. Spring 2004 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
129. **Chang, MN**, K Gardner, HH Mahmoud. Spring 2004 COG Study Progress Report, POG 9917: A Pilot Study of Dose Intensification of Methotrexate in Patients with Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkin's Lymphoma and B-Cell ALL.

130. **Myron Chang** and Meenakshi Devidas (2005). Two stage-designs for phase II window studies. 2005 Proceedings for the Joint Statistical Meetings, Biopharmaceutical Section. [CD-ROM].
131. **Chang, MN**, M Abromowitch. Fall 2005 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.
132. **Chang, MN**, Gerbing R, Buxton A, CH Fu, MA Champagne. Fall 2005 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
133. **Chang, MN**, T Griffin. Fall 2005 COG Study Progress Report, ANHL0121: A Phase II Stoposide (ICE) Chemotherapy In Children with Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia.
134. **Chang, MN** and JM Kraveka. Fall 2005 COG Study Progress Report, :ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
135. **Chang, MN**, K Gardner, R Harris. Fall 2005 COG Study Progress Report, A5962: A pilot study of peripheral blood stem cell transplant (PBSCT) after preparative therapy consisting of Cyclophosphamide, Carmustine (BCNU), and Etoposide (CBV) for recurrent and primarily refractory Hodgkin's and non-Hodgkin's Lymphoma.
136. **Chang, MN**, K Gardner, RD Castleberry. Fall 2005 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
137. **Chang, MN** and M Devidas (2005). Two stage-designs for phase II window studies. 2005 Proceedings for the Joint Statistical Meetings, Biopharmaceutical Section. [CD-ROM].
138. **Chang, MN**, K Gardner, RD Castleberry. Spring 2005 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.

139. **Chang, MN**, K Gardner, TC Griffin. Spring 2005 COG Study Progress Report, ANHL0121: A Phase II Study of Rituximab and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy In Children with Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia.
140. **Chang, MN**, K Gardner, M Abromowitch. Spring 2005 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.
141. **Chang, MN**, K Gardner, JM Kraveka. Spring 2005 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
142. **Chang, MN**, K Gardner, MS Cairo. Spring 2005 COG Study Progress Report, ANHL01P1: A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy.
143. **Chang, MN**, K Gardner, CH Fu, MA Champagne. Spring 2005 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
144. **Chang, MN**, K Gardner, C Hurwitz. Spring 2005 COG Study Progress Report, POG 9720: A Phase II Study of Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia.
145. **Chang, MN**, H Chen, CH Fu, MA Champagne. Fall 2006 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
146. **Chang, MN**, H Chen, JM Kraveka. Fall 2006 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
147. **Chang, MN**, H Chen, M Abromowitch. Fall 2006 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.

148. **Chang, MN**, H Chen, G Lew. Fall 2006 COG Study Progress Report, AALL0433: Intensive treatment for intermediate-risk relapse of childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized trial of vincristine strategies.
149. **Chang, MN**, H Chen, RD Castleberry. Fall 2006 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
150. **Chang, MN**, CH Fu, MA Champagne. Spring 2006 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
151. **Chang, MN**, Wang CG, T Griffin. Spring 2006 COG Study Progress Report, ANHL0121: A Phase II Stoposide (ICE) Chemotherapy In Children with Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia.
152. **Chang, MN**, PW McGrady, JM Kraveka. Spring 2006 COG Study Progress Report: ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
153. **Chang, MN**, M Abromowitch. Spring 2006 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.
154. **Chang, MN**, Gerbing R, Buxton A, RD Castleberry. Spring 2006 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
155. Savasan, S, S Buck, SC Raimondi, H Weinstein, **MN Chang, Y Ravindranath** (2007). CD 36 expression in children acute megabaryoblasts leukemia and I vitro drug sensitivity. Leukemia.
156. **Chang, MN**, H Chen, M Abromowitch. Fall 2007 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.

157. **Chang, MN**, H Chen, G Lew. Fall 2007 COG Study Progress Report, AALL0433: Intensive treatment for intermediate-risk relapse of childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized trial of vincristine strategies.
158. **Chang, MN**, H Chen, CH Fu, MA Champagne. Fall 2007 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
159. **Chang, MN**, H Chen, JM Kraveka. Fall 2007 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
160. **Chang, MN**, H Chen, RD Castleberry. Fall 2007 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
161. **Chang, MN**, H Chen, JM Kraveka. Spring 2007 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
162. **Chang, MN**, H Chen, RD Castleberry. Spring 2007 COG Study Progress Report, AAML0122: Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine, Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia.
163. **Chang, MN**, H Chen, CH Fu, MA Champagne. Spring 2007 COG Study Progress Report, AAML0123: A Phase II Study of Gleevec in Ph+ Chronic PAAhase Chronic Myelogenous Leukemia.
164. **Chang, MN** and Jacqueline M. Kraveka. Fall 2008 COG Study Progress Report, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine.
165. **Chang, MN** and Glen Lew. Fall 2008 COG Study Progress Report, AALL0433: Intensive treatment for intermediate-risk relapse of childhood B-

Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized trial of vincristine strategies.

166. **Chang, MN** and Minnie Abromowitch. Fall 2008 COG Study Progress Report, A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma.

Abstract (refereed)

1. **Ravindranath Y**, Hamre M, Becton D, Buck S, Stout M, Thomas R, **Chang M**, Weinstein H (1999). Multidrug resistance gene (MDR1) expression and cytotoxicity to daunorubicin and cytarabine in childhood acute myeloid leukemia (AML). Presented at the 1999 Joint Meeting of the International Society of Pediatric Oncology (SIOP) and Amer. Soc. Of Pediatric Hem/Onc, Sept 13-18, 1999, Montreal, Quebec, Canada. *Med Ped Oncol* 33(3): 148, abstract # O-11.
2. **Massey GV**, Zipursky A, Doyle JJ, Taub JW, Ravindranath Y, **Chang MN**, Weinstein JJ (2000). A prospective study of the natural history of transient myeloproliferative disorder (TMD) in neonates with Down Syndrome (DS): A Pediatric Oncology Group (POG) Study. Presented at the 42nd annual meeting of the American Society of Hematology (ASH), San Francisco, CA, Dec. 1-5, 2000. *Blood* 96(11) (part 1 of 2): 744a, abstract #3220.
3. **Kraveka JM**, Weinstein HJ, Hutchinson RE, **Chang M**, Kepner J, Schwenn M, Tarbell N, Desai S, Murphy SB, Laver JH (2003). Pediatric anaplastic large cell lymphoma; results of a randomized phase III pediatric oncology group trial of APO versus APO + intermediate dose methotrexate/high dose ARA-C (POG #9315). *Meeting Proceedings American Society for Clinical Oncology*, 3196a.
4. **S Desai**, J Laver, **M Chang**, R Hutchinson, H Weinstein, and S Murphy (2004). Immunophenotype and Outcome of Children and Adolescents with Mediastinal Large Cell Lymphoma- A Pediatric Oncology Group (POG) Study. *Pediatric Blood & Cancer* Vol. 43(4) Pg. 362 Abstract #0.
5. Stine K, Becton D, Dahl GV, Ravindranath Y, Raimondi SC, Fred GE, **Chang MN**, and Weinstein H (2004). Genetic Randomization to Allogeneic Bone Marrow Transplant in Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421. 46th ASH Annual Meeting.
6. Harris R, Morris E, Workentin P, Vlachos A, **Chang MN**, and Cairo MS (2004). Safety and Efficacy of CBV followed by Autologous PBSC Transplant in Children with Lymphoma after Failed Induction or First Relapse-A Children's Oncology Group Stud. 46th ASH Annual Meeting.

7. Liu H, CM Yuan, RC Braylan, **MN Chang**, JR Wingard, JS Moreb (2006). Flow cytometric disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. *Blood*, 108: 5014.
8. Champagne MA, CH Fu, **MN Chang**, et al. (2006) Imatinib in children with newly diagnosed chronic phase myelogenous leukemia: AAML0123 COG study. *Blood*, 607a, Abstract.
9. Lacayo NJ, M O'Brien, S Jain, S Meshinchi, R. Ronald, D Juric, **MN Chang**, et al. (2006). Gene Expression profiling predicts outcome in de novo acute myeloid leukemia with normal karyotype: Results of Children's Oncology Group (COG) study POG # 9421. *Blood*, 108: 1915.
10. Stine K, D Becton, GVH Dahl, Y Ravindranath, SC Raimondi, F Behm, **MN Chang**, R Arceci (2006). TBI and allogeneic BMT do not appear to hinder growth in pediatric patients with AML treated on POG 9421. *Blood*, 108:3677.
11. O'Brien M, J Taub, K Stine, **MN Chang**, Y Ravindranath, D Becton, GVH Dahl (2006). Excessive Cardio toxicity despite excellent leukemia-free survival for pediatric patients with Down syndrome (DS) and acute myeloid leukemia (AML): results from POG (Pediatric Oncology Group) protocol 9421. *Blood*, 108:559.
12. Brown P, E McIntyre, R Rau, TA Alonzo, S Meshinchi, N Lacayo, **MN Chang**, R Arceci, D Small (2006). Incidence and clinical significance of nucleophosmin mutations in childhood AML: a Children's Oncology Group study. *Blood*, 108:221.
13. Hsu JW, H Liu, K Jamieson, W Hou, **MN Chang**, P Ahrens, RC Braylan, JR Wingard (2007). Wilm's tumor 1 gene expression is a useful marker for minimal residual disease in acute myeloid leukemia. *Blood*, Nov 2007; 110: 4240.
14. Coenen EA, SC. Raimondi, J Harbott, M Zimmermann, BV. Balgobind, TA. Alonzo, A Auvrignon, HB Beverloo, **Myron Chang**, et al. (2010). Clinical impact of additional cytogenetic aberrations and complex karyotype in 756 pediatric 11q23/*MLL*-rearranged AML: results from an international retrospective study. ASH annual meeting.
15. Tan SA, T Cuellar, K Lavender, M Coons, JE Cline, **MN Chang**, KE Behrus, and EH Huang (2012). Pilot study to prevent readmission after new Ileostomies. The Souther Surgical Association.
16. Subbiah S, RA Brown, **MN Chang**, CR Cogle, JW Hiemenz, WS may, J Moreb, and M Norkin, JR Wingard, B Wirk, and JW Hsu (2011). CECA results in improved response rates and ability to proceed to stem cell transplantation in adult refractory or relapsed acute myeloid leukemia. ASH Annual Meeting Abstracts 2011 118:4299.

17. Santos N, RA Brown, **MN Chang**, CR Cogle, JW Hiemenz, WS may, JS Moreb, M Norkin, JW Wingard, B Wirk, and JW Hsu (2011). Negative correlation between the hematopoietic stem cell transplant comorbidity index (HCT-CI) and total hospital stay in patients who underwent unrelated donor hematopoietic stem cell transplantation (HSCT). ASH Annual Meeting Abstracts 2011 118:4462.
- 18.

Submitted Papers

1. Scharf VF, JP Farese, AR Coomer, R Milner, D Taylor, ME Salute, DW Siemann, **MN Chang**, and D Neal. Bevacizumab inhibits angiogenesis and delays growth of xenografted canine osteosarcoma in murine model.
2. Wei Hou, **MN Chang**, SH Jung, and Y Li. Designs for randomized phase II clinical trials.
3. Goodison S, **MN Chang**, Y Dai^b, J Kim, V Urquidi, CJ Rosser. Validation of a novel combinational urine-based biomarker assay in the detection of bladder cancer.
4. Choi EJ, YH Kim, SW Choe, EM Garrido-Martin, YG Tak, **MN Chang**, B Sorg, YJ Lee, and SP Oh. Enhanced angiogenic response in ALK1-deficient endothelial cells underlies the development of arteriovenous malformation in a SMAD-independent manner.
5. Shenoy AK, EA Butterworth, RC Fisher, L Pi, LJ Chang, HD Appelman, **MN Chang**, EW Scott, EH Huang. High Wnt-Activity Confers Sustained Tumor-Initiating Potential on Human Precursor-Colon Cancer Stem Cells. Submitted to Cancer Research (5/11/2012).

Work in Progress:

Chang MN. Attained versus planned phase II clinical trials.

Presentations:

1. **Chang MN** “Strong Consistency of a Nonparametric Estimator with Doubly Censored Data.” Regional Probability-Statistics Meeting at Naval Academy, MD, Spring 1984.
2. **Chang MN** “Confidence Intervals Following Sequential Phase II Trials.” Thirteenth International Biometric Conference, Seattle, WA, August 1986.
3. **Chang MN** “Nonparametric Estimations with Double-Censored Data.” Joint Statistical Meeting, Las Vegas, NV, August 1985.
4. **Chang MN** “Moments of the Kaplan-Meier Estimator.” IMS Meeting, Blackhill, VA, May 1987.
5. **Chang MN** “Enumeration of the Optimal Designs for a Grouped Sequential Trial with Binomial Outcome.” Eighth Annual Meeting, Society for Clinical Trials, Atlanta, May 1987.
6. **Chang MN** “Weak Convergence of a Self-Consistent Estimator of the Survival Function with Doubly Censored Data.” Joint Statistical Meeting, San Francisco, CA, August 1987.
7. **Chang MN** “Optimal Designs for Group Sequential Clinical Trials.” Joint Statistical Meeting, New Orleans, LA, August 1988.
8. **Chang MN** “Berry-Esseen Bound for the Kaplan-Meier Estimator.” Joint Statistical Meeting, Washington, D.C., August 1989.
9. **Chang MN** “Edgeworth Expansion for the Kaplan-Meier Estimator.” Joint Statistical Meeting, Washington, D.C., August 1989.
10. **Chang MN** “Nonparametric Estimation with Doubly Censored Data.” Invited Presentation, Academia Sincia, Beijing, China, July 1989.
11. **Chang MN** “An Algorithm for the Exact Distribution of the Kaplan-Meier Estimator Under the Proportional Model.” Joint Statistical Meeting, Anaheim, CA, August 1990.
12. **Chang MN** “The Predictive Distribution of the Logrank Test Statistic at the End of a Randomized Clinical Trial.” Invited Presentation, Pharmaceutical Statistics Meeting, International Chinese Statistical Association, Rutgers University, May 1992.
13. **Chang MN** “Interim Analysis for Randomized Clinical Trials: Simulating the Predictive Distribution of the Logrank Test Statistics.” Joint Statistical Meeting, Boston, August 1992.

14. **Chang MN** “Introduction to Group Sequential Procedures.” Merck & Co., Inc., Clinical Biostatistics and Research Data Systems, November 1992.
15. **Chang MN** “Inference with Non-Ignorable Missing Data from a Random Effects Model.” Joint Statistical Meeting. San Francisco, California, August 1993.
16. **Chang MN** “Group Sequential Designs Using Both Type I and Type II Error Probability Spending Function.” Joint Statistical Meeting, San Francisco, California, August 1993.
17. **Chang MN** “P-Values for Group Sequential Testing.” International Chinese Statistical Association 1994 Applied Statistics Symposium, Washington, D.C., May 1994.
18. **Chang MN** “Trail Probability Approximation for One Sample U-Statistics by Saddle-Point Method.” Joint Statistic Meeting, Toronto, Canada, 1994.
19. **Chang MN** “Reduction in Burden of Illness: A New Efficacy Measure For Prevention Trials.” Statistics Department, University of Florida, April, 1995.
20. **Chang MN** “Isotonic Window Estimators of Survival Functions Based on Observations That Are Right or Left Censored.” Joint Statistics Meetings, Orlando, August, 1995.
21. **Chang MN** “Isotonic Window Estimation of the Distribution Function with Current Status Data.” Statistics Department, University of Florida, October 1995.
22. **Chang MN** “Tests for Incidence Rate and Case Severity in Randomized Clinical Trials.” The International Biometric Society, Eastern North American Region, 1996 Spring Meeting, Richmond Virginia, March 1996.
23. **Chang MN** “Parametric and Nonparametric Tests for Incidence Rate and Case Severity in Randomized Clinical Trials.” International Chinese Statistical Association 1996 Applied Statistics Symposium, Baltimore, Maryland, June, 1996.
24. **Chang MN.** “A Two-Sample Combinative Rank-Based Test for Right Censored Data”, Joint Statistical Meeting, TX. 1998.
25. **Chang MN, JJ Shuster, and JL Kepner.** “Sample sizes based on an exact unconditional test for Phase II Clinical Trials with Historical Control”, *The 20th International Biometric Conference* in Berkeley, California. 2000.
26. **Chang MN, JJ Shuster, and JL Kepner.** “Exact Unconditional Test for Phase II Clinical Trials with Historical Controls”, *Joint Statistical Meetings* in Indianapolis, Indiana. 2000.

27. London WB and **MN Chang**. “Two Stage Designs for Stratified Phase II Clinical Trials”, Joint Statistical Meetings in Atlanta, Georgia. 2001.
28. Shuster JJ, **MN Chang**, and JL Kepner. “Sample Size Algorithm for Phase II Cancer Trials and tissue Banking”, Invited Technical Exhibits at Joint Statistical Meetings in Atlanta, Georgia. 2001.
29. **Chang MN**. “Mapping Quantitative Trait Loci from a Genetic Linkage Map”, Invited presentation at the 982nd American Mathematical Society Meeting in Orlando, FL. 2002.
30. **Chang MN**. “Improved Confidence Intervals Following a Group Sequential Phase II Clinical Trial for a Binomial Parameter”, Seminar presented at the Department of Statistics, Children’s Oncology Group. Fall 2002.
31. **Chang MN**. “Score Statistics for Mapping Quantitative Trait Loci”, Statistics Department Seminar. Fall, 2003.
32. **Chang MN**. “Statistical Application to Genetics”, Invited presentation at Tongji University, Shanghai, China. 2003.
33. London WB and **MN Chang** “One- or Two- Stage Designs for Stratified Phase II Clinical Trials”, Joint Statistical Meetings, San Francisco. August, 2003.
34. **Chang MN**. “On the Maximum Total Sample Size of a Group Sequential Test about Binomial Proportions”, Joint Statistical Meetings, Toronto, Canada. August, 2004.
35. **Chang MN**. “Optimal Designs for Clinical Trials”, Invited presentation at Tongji University, Shanghai, China. 2004.
36. **Chang MN**. “Minimizing the Maximum Total Sample Size for Group Sequential Phase II Clinical Trials”, Biostatistics Department Seminar. Fall, 2004.
37. **Chang MN**. “Designs for Phase II window Studies”, Joint Statistical Meetings, Minneapolis, August, 2005.
38. **Myron Chang** and Meenakshi Devidas (2005), Designs for phase II window studies, Joint Statistical Meetings, Minneapolis, MN.
39. Castleberry, R, M Loh, N Jayaprakash, A Peterson, V Casey, **M Chang**, B Widemann, P Emanuel (2005), Phase II Window study of the Farnesyltransferase inhibitor R115777 in untreated Juvenile Myelomonocytic leukemia. ASH Meeting.

40. Hasle, H, T Alonzo, A Avrignon, C Behar, **M Chang** et al (2005), Acute Myelogenous Leukemia – Therapy, excluding transplantation. ASH Meeting.
41. Kuo, D, NJ Lacayo, D Hoang, D Juric, SC Raimondi, D Liu, **MN Chang**, et al (2005), Array CGH Discovers Novel Genomic signature in de novo acute myeloid leukemia: results of Children’s Oncology Group Study POG #9421.
42. **Chang MN** (2006). Estimation of multiple response rates in clinical trials with missing observations. 2006 Joint Statistical Meetings.
43. Champagne MA, CH Fu, **MN Chang**, et al. Imatinib in children with newly diagnosed chronic phase myelogenous leukemia. 2006 ASH.
44. **Chang MN**, M Devidas, J Anderson (2006, April). Designs for Phase II Window Studies. Poster session presented at the College of Medicine Annual Research Day, University of Florida.
45. Lacayo NJ, M O’Brien, S Jain, S Meshinchi, R. Ronald, D Juric, **MN Chang**, et al. Gene Expression profiling predicts outcome in de novo acute myeloid leukemia with normal karyotype. 2006 ASH Poster.
46. **Chang MN**, M Devidas, J Anderson (2006, May). Designs for Phase II Window Studies. Poster session presented at the Annual UF Shands Cancer Center, University of Florida.
47. **Chang MN**. “Estimation of correlated response rates in clinical trials”. 2007 Joint Statistical Meetings, Salt Lake City.
48. Hsu JW, H Liu, K Jamieson, W Hou, **MN Chang**, P Ahrens, RC Braylan, JR Wingard (2007). Wilm’s tumor 1 gene expression is a useful marker for minimal residual disease in acute myeloid leukemia. 2007 ASH.
49. **Chang MN**. “Testing the stochastic ordering of discrete distributions”. IMS International Meetings, Shanghai, China, 2008.
50. L Dickerson, N Desai, E Walden, **MN Chang**, Y Jiang, TJ. George, Jr. Osteonecrosis of the jaw incidence and contributing risk factors in cancer patients treated with intravenous bisphosphonates: A Veterans Administration Healthcare study. American Society of Clinical Oncology Annual Meeting, 2008.
51. L Dickerson, N Desai, E Walden, **MN Chang**, Y Jiang, TJ. George, Jr. Osteonecrosis of the jaw incidence and contributing risk factors in cancer patients treated with intravenous bisphosphonates: A Veterans Administration Healthcare study. Department of Medicine, College of Medicine, University of Florida, Research Day on June 4th, 2008.

52. Hutchison RE, JH Laver, **MN Chang**, T Muzzafar, S Sesai, et al. (2008). Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: A Children's Oncology Group Study. American Society of Pediatric Hematology/Oncology's 21st Annual Meeting, Cincinnati, OH, 2008.
53. **Chang MN** (2008). "Testing the stochastic ordering of discrete distributions". IMS International Meetings, Shanghai, China.
54. **Chang MN** (2008). "Stochastic ordering of discrete distributions". 1st International Symposium on Biopharmaceutical Statistics, Shanghai, China.
55. J Kirpenstein, M Kils, NJ Bacon, SS Waltman, B Seguin, M kent, J Liptak, R Straw, **MN Chang**, Y Jiang, JP Farese, and SJ Withrow (2008). Biological behavior and clinical outcome of 28 cases of canine appendicular chondrosarcoma treated with amputation: A Veterinary Society of Surgical Oncology retrospective study. 2008 annual meeting of the Veterinary Cancer Society.
56. M Abromowitch, A Termuhlen, J Lynch, **M Chang**, SL Perkins, T Gross, HJ Weistein, and J Finlay (2009). High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma: results of randomized arms of COG A5971. 2009 ASH meeting.
57. A Termuhlen, J Lynch, SL Perkins, T Gross, HJ Weistein, J Finlay, **M Chang**, and M Abromowitch (2009). Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on COG A5971: A report from the Children's Oncology Group. 2009 International NHL meeting.
58. Yao Li, A Berg, **M Chang**, and R WU (2009). An epidemiological model for genetic mapping of viral pathogenesis. 2009 ENAR.
59. BV Balgobind, J Harbott, S Raimondi, M Zimmermann, T Alonzo, A Auvrignon, HB Beverloo, **M Chang** et al (2009). Outcome in childhood acute myeloid leukemia with different rearrangements of MLL gene: an international retrospective study. 2009 EHA.
60. **Chang, MN**. (2009) Testing statistical hypotheses on stochastic ordering of discrete distributions. 2009 Joint Statistical Meetings. Washington DC.
61. A Termuhlen, J Lynch, SL Perkins, T Gross, HJ Weistein, J Finlay, **M Chang**, and M Abromowitch (2009). Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on COG A5971: A report from the Children's Oncology Group. 2009 International NHL meeting.
62. Yao Li, A Berg, **M Chang**, and R WU (2009). An epidemiological model for genetic mapping of viral pathogenesis. 2009 ENAR.

63. **Chang MN**. Two-Stage Designs For Phase II Clinical Trials with Heterogeneous Patient Populations. 2010 Joint Statistical Meetings. Vancouver, Canada.
64. Coenen, EA, SC. Raimondi, J Harbott, M Zimmermann, BV. Balgobind, TA.
65. Alonzo, A Auvrignon, HB Beverloo, **Myron Chang**, et al. (2010). Clinical impact of additional cytogenetic aberrations and complex karyotype in 756 pediatric 11q23/*MLL*-rearranged AML: results from an international retrospective study. 2010 ASH.
66. Peter V. Draganov, **Myron N. Chang**, John Lieb, Baharak Moshiree, Steven Polyak, Shahnaz Sultan, Dennis Collins, Amitabh Suman, John F. Valentine, Mihir S. Wagh, Samir L. Habashi, Christopher E. Forsmark (2010). Randomized controlled trial of two types of biopsy forceps for polypectomy of small colorectal polyps. Digestive Disease Week 2010.
67. Jacqueline Kraveka, Sheila Weitzman, Lynette Smith, James Lynch, **Myron Chang**, et al. (2010). Advanced-Stage Anaplastic Large-Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial with Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation with a Regimen Including Vinblastine: A Report from the Children's Oncology Group. 2010 ASCO meeting.
68. Rosenau, E, M Sugrue, **M Chang**, D Fisk, M Haller, S Staba, L Eldjerou, W Slayton, and JR Wingard (2010). Characteristics of Autologous Umbilical Cord Blood. 2010 Annual ISCT conference
69. Paul Okunieff, **Myron Chang**, and Michael Milano (2010). Patterns of Recurrence After Curative-Intent Radiation for Oligometastases Confined to One Organ. 5th International Novalis Circle Conference, Feldkirchen, Germany.
70. Christopher Williams, **Myron Chang**, Bryan Schurfranz, Joseph Tepas, and Jose Costa (2010). Value of the acute emergency care setting for initial prostate cancer screening. 2010 National Medical Association meeting.
71. Gang Zheng, Tammy Euliano, **Myron Chang**, and Michael E. Mahla. Transition to practice (TTP): A small group teaching in senior residents of anesthesiology. 2010 SGEA conference. **Received the Outstanding Poster Award.**
72. Emina Huang, **Myron Chang**, et al. Tumor growth in pellet mice 2010 seminar, Department of Surgery, College of Medicine, University of Florida.
73. Wei Hou, Keith Muller, Paul Okunieff, Michael Milano, and **Myron Chang**. Estimating cure rates from survival data with reference to the survival distribution of general population. 2011 ENAR meetings, Miami, USA.

75. **Chang MN** (2011). Two-stage designs with additional futility tests for phase II clinical trials with heterogeneous patient population. Annual International Symposium on the Evaluation of Clinical Trials Methodologies and applications. Beijing, China.
76. Moreb JS, D Salmasinia, H Leather, A Davis, JW Hsu, L Wiggins, CR Cogle, **MN Chang**, JR Wingard (2011). Single versus tandem autologous stem cell transplantation (ASCT) for multiple myeloma patients and role of second salvage transplant: A single center prospective phase II study. Tandem Transplant Meeting.
77. **Chang MN** (2011). Designs of clinical trials. Biostatistics Department Seminar.
78. **Chang MN**, SH Jung, and S Wu (2011). Two-stage designs with additional futility tests for phase II clinical trials with heterogeneous patient populations. Fourth Annual International Symposium on the Evaluation of Clinical Trials Methodologies and Applications. Beijing, China.

UNIVERSITY GOVERNANCE AND SERVICE

a) Cancer Center Committees

1) Served as a member of the Protocol Review and Recourse Utility Committee (PRRUC) of Cancer Center, 2001 - present.

The PRRUC holds a monthly meeting to review all protocols of the cancer clinical trials initiated by UF faculty, cooperative groups, and pharmaceutical companies. The purpose of the review is to decide whether the UF Cancer Center should participate in these studies. Dr. Chang's duty is to provide a scientific review of each protocol, especially its objectives, background, data collection, safety issues, statistical design including interim monitoring, and statistical analysis. Dr. Chang provides critical suggestions to the committee for the acceptability of the study. After the PRRUC meetings, Dr. Chang takes care of follow-up discussions with the study chair for necessary modifications of the statistical section in the protocol.

2) Served as a member of Data and Safety Monitoring Committee (DSMC) of the Cancer Center, 2004 - present.

The DSMC monitors the progress of cancer trials initiated by UF and the safety of participants, such as the adherence to defined accrual goals, interim assessment of toxicity and response, and data quality assurance. Dr. Chang has helped the DSMC with

the agenda and the template of reports for study chairs. Dr. Chang has played a key role in the committee because of his working expertise in COG.

3) **Served as a member of Data and Safety Monitoring Committee** for the study entitled “Depth of General Anesthesia and Postoperative Mortality” conducted by Drs. Christoph N. Seubert and Mary Herman in GCRC, 2005 - present.

4) **Member: Pediatric Oncology Working Group, Shands Cancer Center, University of Florida, 2003-2005.**

b) College Committees

1) **Served as a member of Faculty Incentive Committee, 2011-2012**

2) **Served as a member of Tenure & Promotion Committee, 2011-2012**

c) Department Committees

1) **Served on Biostatistics department Tenure and Promotion committee, 2011-2012.**

2) **Served as Faculty Search Committee member, 2010-2011.**

3) **Served as Faculty Search Committee chair, 2007-2008.**

4) **Served as Faculty Search Committee member, 2006-2007.**

5) **Served as the Search Committee Chair for faculty positions and for the position of the director of the Division of Biostatistics, 2005-2006.**

Developed job descriptions in professional journals.

Interviewed upwards of 10 candidates during the 2005 Joint Statistical Meetings.

Contacted many potential candidates by phone and email.

Reviewed application material for more than 100 applicants.

Arranged 13 interviews.

Organized more than 10 Search Committee meetings.

6) **Served as Faculty Search Committee member, CLAS/Genetics Institution, 2003-2004.**